{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Will evaluate other clinical outcomes using the methods of Kaplan-Meier.","groups":[{"description":"Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLenalidomide: Given PO\n\nNivolumab: Given IV\n\nPharmacological Study: Correlative studies","id":"OG000","title":"Treatment (Lenalidomide, Nivolumab)"}],"populationDescription":"data was not collected and analyzed","reportingStatus":"POSTED","timeFrame":"Time from study entry until disease progression or death at trial closure for the per protocol population, assessed up to 3 years","title":"Progression Free Survival (PFS)","type":"SECONDARY"}